Cargando…

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and measured Lp(a) secretion from human hepatocyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villard, Elise F., Thedrez, Aurélie, Blankenstein, Jorg, Croyal, Mikaël, Tran, Thi-Thu-Trang, Poirier, Bruno, Le Bail, Jean-Christophe, Illiano, Stéphane, Nobécourt, Estelle, Krempf, Michel, Blom, Dirk J., Marais, A. David, Janiak, Philip, Muslin, Anthony J., Guillot, Etienne, Lambert, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	PRECLINICAL RESEARCH
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753417/ https://www.ncbi.nlm.nih.gov/pubmed/29308438 http://dx.doi.org/10.1016/j.jacbts.2016.06.006

Ejemplares similares

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
por: Chemello, Kévin, et al.
Publicado: (2020)

Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ(1)-HDL, α-HDL, and triglyceride-rich lipoproteins
por: Chétiveaux, Maud, et al.
Publicado: (2020)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
por: Huang, Hui-Chun, et al.
Publicado: (2022)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
por: Catapano, Alberico L., et al.
Publicado: (2017)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

High Glucose Activates YAP Signaling to Promote Vascular Inflammation
por: Ortillon, Jeremy, et al.
Publicado: (2021)

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
por: Ramanathan, Aarti, et al.
Publicado: (2016)

Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies
por: Nolain, Patrick, et al.
Publicado: (2022)

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
por: Lunven, Catherine, et al.
Publicado: (2014)

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
por: Andersson, Claes R., et al.
Publicado: (2022)

Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study
por: Poirier, Julie, et al.
Publicado: (2021)

Consequences of blunting the mevalonate pathway in cancer identified by a pluri-omics approach
por: Goulitquer, Sophie, et al.
Publicado: (2018)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
por: Kastelein, John J. P., et al.
Publicado: (2014)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species
por: Kaabia, Zied, et al.
Publicado: (2018)

RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017)

Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019)

Acute Kidney Injury Induces Remote Cardiac Damage and Dysfunction Through the Galectin-3 Pathway
por: Prud’homme, Mathilde, et al.
Publicado: (2019)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
por: East, Cara, et al.
Publicado: (2022)

Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways
por: Johnstone, Andrea L., et al.
Publicado: (2019)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Deciphering SARS-CoV-2 Virologic and Immunologic Features
por: Lebeau, Grégorie, et al.
Publicado: (2020)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
por: Gao, Fei, et al.
Publicado: (2022)

Alirocumab in Post ACS Patients - Saving Lives at a Premium
por: George, Melvin, et al.
Publicado: (2022)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia
por: Ying, Qidi, et al.
Publicado: (2023)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rt9lg1vnramqc6caeahvguhjhs